Thursday, 5 September 2013

Alex Ruus on BNN: We Think It’s (Acasti’s Capre) Going To Be A Category Killer


Acasti Pharma
TSX V: APO NASDAQ: ACST

Shares Outstanding: 79.4 million
Fully Diluted: 91.4 million
***************************** 
Neptune Technologies and Bioressources
TSX: NTB – NASDAQ: NEPT
Basic Shares: 60.0 million
Fully Diluted: 67.5 million
**************************************


Last evening, Alex Ruus, Portfolio Manager at Blumont Capital, was a guest on Market Call, a popular show on Canada’s Business News Network (BNN). In his segment he named Neptune Technologies as one of his Top Picks. The reasons he gave are as follows:
  • Neptune sells Neptune Krill Oil (NKO) which produces nice cash flow.
  • Mr. Ruus acknowledged that NKO helps his cholesterol.
  • Neptune owns 60% of Acasti.
  • Acasti is responsible for developing the pharmaceutical angle of NKO – Capre.
  • This is a market that historically has been as big as $20 billion in sales when Lipitor was pre-generic.
  • We think it is going to be a category killer and will be taken over by one of the big pharmas once they get into phase 3 trials.
To view his commentary on Neptune as a top pick, click here (2:28 mark).

Also in the episode during “Market Call Minute,” a caller asked Mr. Ruus about Acasti Pharma.  At the 6:08 mark of this clip,  he acknowledged that he thinks Acasti is definitely a strong buy. He also said the Phase II Open Label results that were recently released were good.